65,437 trials
Metformin Adverse Reaction · Tolerance
Primary: Treatment Satisfaction as Measured by the Treatment Satisfaction Questionnaire for Medication (TSQM II) — 39.42; 51.92 score on a scale
Healthy
Primary: Peak Plasma Concentration (Cmax) — 4.141; 3.908 μg/mL
Major Depressive Disorder
Primary: Change From Pre-treatment to Post-treatment (10 Weeks), Measured by the Hamilton Rating Scale for Depression, 17 Item Version (HRSD-17). — 15.73; 15.70; 9.17; 14.05…
Chronic Urticaria
Primary: Change in the Basophil Proteome — 4; 0; 3 Participants
Pulse Oximetry
Primary: Accuracy Root Mean Square (ARMS) Per Data Pair — 2.57; 2.57 percentage of oxygen saturated hemoglobi
Intrauterine Devices
Primary: Crude Incidence Rate of Uterine Perforation Stratified by Breastfeeding Status Among Women Within 52 Weeks Postpartum-first Observed IUD Insertions — 4.25; 2.50 per 1000…
Pain
Primary: Rate of Change in Pain Intensity Per Hour — 1.3; 0.3 Score on a scale per hour — p=<0.001
Breast Cancer
Primary: Median Change in 6-month Tumor Volume Compared to Baseline Using Mammography — -5.0 change in tumor volume (mm) — p=0.07
Amyloidosis; Heart (Manifestation) · Senile Cardiac Amyloidosis
Primary: Changes in Strain Echocardiography — 9.1 percent LV shortening
Anterior Cruciate Ligament Injury
Primary: Change in Peak Knee Extension Moment Symmetry — 50.1; 44.2; 44.6; 40.6 % Symmetry
Chronic Scar Pain
Primary: Time to Onset of Effect in the Spontaneous Numerical Rating Scale (NRS) Score — 4.41; 15.11; 29.45; 0.65 days
Alcoholic Intoxication · Neurobehavioral Manifestations
Primary: Self-reported Residual Effects of Heavy Drinking — 4.3; 1.93 scores on a scale
Zika Virus · Zika Virus Infection · Virus Diseases
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 7 Days After Each Product Administration (Part A and Part B) — 5; 2; 2; 291 Participants
Obstructive Sleep Apnea
Primary: 24-h, Wake and Sleep Period Systolic and Diastolic Blood Pressure — 143; 133; 136; 87 mmHg
Multiple Myeloma
Primary: Participants With Id-specific Immunity — 0; 8 Participants